Eli Lilly’s Zepbound is still viewed as the leading weight-loss shot, according to a market analyst who compared the drug to a rival injection from Pfizer. The comment comes as drugmakers race to meet ...

The company has not disclosed pricing or a launch timeline. The approval also comes as Novo Nordisk's Wegovy nears patent expiry later this month, potentially paving the way for lower-cost copycat ...